Watch and Wait: Rethinking Rectal Cancer Treatment for Better Quality of Life
"Can avoiding surgery after chemoradiation lead to a happier, healthier recovery for rectal cancer patients?"
The standard treatment for locally advanced rectal cancer often involves a combination of chemotherapy, radiation, and surgery to remove the rectum (total mesorectal excision or TME). While this approach is effective at treating the cancer, it can also lead to long-term side effects that significantly impact a patient's quality of life. These side effects can include bowel dysfunction, sexual problems, and urinary issues.
However, a subset of patients – about 15-20% – experience a complete or near-complete response to chemotherapy and radiation, where the tumor disappears or shrinks dramatically. This raises a crucial question: do these patients necessarily need surgery, or can they be safely monitored with a 'watch-and-wait' approach?
The 'watch-and-wait' strategy involves closely observing the patient through regular checkups, scans, and examinations, intervening with surgery only if the cancer regrows. The goal is to preserve the rectum and its functions, thereby improving the patient's quality of life. This article explores the findings of a study comparing the quality of life of rectal cancer patients who underwent watch-and-wait versus those who had standard surgery after chemoradiation.
Why Watch and Wait Matters
Watch-and-wait management is an organ-preserving approach being considered for selected people with rectal cancer who show no detectable tumor after treatment. Rather than proceeding directly to rectal removal, care may shift toward close monitoring. Its potential value lies in balancing cancer control with quality-of-life considerations, although suitability depends on treatment response and ongoing clinical assessment.
Surveillance and Standardization
Watch and wait is generally considered for selected patients with no evidence of tumor after treatment and requires extensive clinical, endoscopic, and radiologic surveillance. Advances in neoadjuvant chemoradiotherapy have increased tumor regression rates, helping make the strategy a viable option for some patients. However, prospective studies have used four watch-and-wait-specific primary endpoints and four methods for calculating regrowth rates, highlighting the need for standardization. Critical appraisals also identify continuing tensions involving organ preservation, oncological safety, response assessment, local regrowth, and practical implementation.
From Organ Preservation to Wider Application
The history of watch and wait has been shaped by changes in organ-preserving treatment pathways and by efforts to move the strategy from clinical research into practice. Recent discussions have also examined whether its rationale might extend to carefully selected patients with metastatic rectal cancer. Emerging data described in 2025 suggest that patients with limited metastatic burden and robust treatment responses may experience organ-preserving benefits without compromising oncological outcomes. At the same time, implementation remains part of the broader and complicated landscape of rectal cancer decision making.
The Study: Comparing Watch-and-Wait to Standard Resection
Researchers in the Netherlands conducted a matched-controlled study to compare the quality of life of patients who underwent a watch-and-wait approach with those who had standard surgery (TME) after chemoradiation. The study included 41 patients in each group, carefully matched for factors like age, sex, tumor stage, and tumor location. All patients had been disease-free for at least two years at the time of the study.
- General quality of life (SF-36, EORTC QLQ-C30)
- Disease-specific quality of life related to rectal cancer and its treatment (EORTC QLQ-CR38)
- Bowel function and defecation problems (Vaizey score, LARS score)
- Sexual function (IIEF for men, FSFI for women)
- Urinary function (IPSS)
What Recent Evidence Is Asking
A 2026 Frontiers review examined PubMed literature from 2020 through 2025, including reviews, randomized controlled trials, and cohort studies of watch and wait for locally advanced rectal cancer and clinical or pathological complete response. Its scope included patient selection, efficacy assessment, current challenges, and future directions. A 2025 report concluded that watch and wait for rectal tumors beyond the reach of digital rectal examination had oncological and rectal-organ preservation rates that did not differ from those in patients with palpable tumors. Another retrospective analysis studied high-risk locally advanced cases treated with total neoadjuvant therapy followed by either surgery or watch and wait between January 2016 and February 2023.
The Risk of Losing the Follow-Up
The watch-and-wait model depends on patients receiving and completing recommended surveillance. A 2024 real-world study examined adherence to surveillance for nonoperative rectal cancer management, sought predictors of poor adherence, and evaluated the effect of adherence on oncological outcomes during the first two years. Its framing, contrasting watch and wait with being lost to follow-up, underscores that nonoperative care is not equivalent to no care. Inadequate follow-up can therefore undermine the safety assumptions on which the strategy depends.
Surgery Versus Organ Preservation
The Memorial Sloan Kettering Cancer Center describes watch and wait as an approach that can preserve quality of life by treating rectal cancer without removing the rectum. Patient-facing guidance from Fight Colorectal Cancer presents watch and wait as active surveillance rather than passive observation, with eligibility, monitoring tests, and questions for the care team forming central parts of the decision. Together, these sources frame the comparison with surgery around both treatment effectiveness and the lived consequences of rectal removal. The approach is not presented as suitable for everyone, but as a choice requiring careful assessment and monitoring.
The Future of Rectal Cancer Treatment
This study adds to the growing body of evidence supporting the watch-and-wait approach as a viable option for select rectal cancer patients who achieve a complete response to chemoradiation. By avoiding surgery, many patients can experience a better quality of life, with fewer bowel, sexual, and urinary problems.
A Careful Balance
Watch and wait reflects a broader effort to tailor rectal cancer treatment to both oncological risk and quality of life. The strategy may be appropriate for selected patients, but it requires reliable assessment and continued surveillance. Its value therefore depends not only on achieving a complete response, but also on whether patients and care teams can sustain the monitoring needed to detect change.
Toward More Reliable Selection
Future progress is likely to depend on improving how clinicians identify complete responses and monitor patients over time. Research may also clarify which patients can safely avoid surgery and how surveillance can be made more consistent. Until those approaches are better established, watch and wait remains a carefully selected treatment pathway rather than a universal replacement for surgery.
Extending the Organ-Preservation Question
The watch-and-wait discussion is beginning to include metastatic rectal cancer, not only non-metastatic disease. Emerging data suggest that carefully selected patients with limited metastatic burden and robust responses to therapy may receive organ-preserving benefits similar to those reported in non-metastatic counterparts. The same source reports that these benefits may occur without compromising oncological outcomes, although the evidence is described as emerging rather than definitive.
Quality of Life Requires Partnership
Watch-and-wait care affects patients beyond the initial treatment decision because it requires sustained participation in surveillance. A 2025 report argues that improving real-world adherence to nonoperative management surveillance requires balancing oncological safety with patient burden and using collaborative, systems-based practices. A separate report examined long-term outcomes and quality of life among patients managed with watch and wait after a clinical complete response to neoadjuvant therapy. These findings place patient experience and the practical demands of follow-up alongside cancer-control goals.
However, it's important to remember that watch-and-wait is not for everyone. Patients need to be closely monitored, and surgery may still be necessary if the cancer regrows. More research is needed to identify the ideal candidates for this approach and to optimize follow-up strategies.
As cancer treatment continues to evolve, the focus is shifting towards personalized approaches that consider not only the effectiveness of the treatment but also its impact on the patient's overall well-being. The watch-and-wait strategy exemplifies this shift, offering a potential path towards a happier, healthier future for some rectal cancer patients.